Document is current
Any future updates will be listed below
-
Authors
Saßmannshausen, Marlene
Behning, Charlotte
Isselmann, Ben
Schmid, Matthias
Finger, Robert P.
Holz, Frank G.
Schmitz-Valckenberg, Steffen
Pfau, Maximilian
,
Agostini, H.
Altay, L.
Atia, R.
Bandello, F.
Basile, P. G.
Behning, C.
Belmouhand, M.
Berger, M.
Binns, A.
Boon, C. J. F.
Böttger, M.
Bouchet, C.
Brazier, J. E.
Butt, T.
Carapezzi, C.
Carlton, J.
Carneiro, A.
Charil, A.
Coimbra, R.
Cozzi, M.
Crabb, D. P.
Cunha-Vaz, J.
Dahlke, C.
de Sisternes, L.
Dunbar, H.
Finger, R. P.
Fletcher, E.
Floyd, H.
Francisco, C.
Gutfleisch, M.
Hogg, R.
Holz, F. G.
Hoyng, C. B.
Kilani, A.
Krätzschmar, J.
Kühlewein, L.
Larsen, M.
Leal, S.
Lechanteur, Y. T. E.
Luhmann, U. F. O.
Lüning, A.
Marques, I.
Martinho, C.
Montesano, G.
Mulyukov, Z.
Paques, M.
Parodi, B.
Parravano, M.
Penas, S.
Peters, T.
Peto, T.
Pfau, M.
Poor, S.
Priglinger, S.
Rowen, D.
Rubin, G. S.
Sahel, J.
Sánchez, C.
Sander, O.
Saßmannshausen, M.
Schmid, M.
Schmitz-Valckenberg, S.
Schrinner-Fenske, H.
Siedlecki, J.
Silva, R.
Skelly, A.
Souied, E.
Staurenghi, G.
Stöhr, L.
Taylor, D. J.
Terheyden, J. H.
Thiele, S.
Tufail, A.
Varano, M.
Vieweg, L.
Wintergerst, L.
Wolf, A.
Zakaria, N.
Thiele, Sarah
-
Funding
Funding for this research was provided by:
BONFOR GEROK Program, Faculty of Medicine, University of Bonn to MS. (O-137.0030)
Innovative Medicines Initiative 2 Joint Undertaking (116076)
BONFOR GEROK Program, Faculty of Medicine, University of Bonn to ST (O-137.0026)
German Research Foundation to ST (TH 2514/2-1)
Rheinische Friedrich-Wilhelms-Universität Bonn
- License Information
-
More Information
Article History
Received: 10 May 2022
Accepted: 22 August 2022
First Online: 2 September 2022
Competing interests
: M.S.: Heidelberg Engineering: non-financial support; Optos: non-financial support, Zeiss: non-financial support, CenterVue: non-financial support. C.B.: No financial disclosures. B.I.: No financial disclosures. M.Sc.: No financial disclosures. R.F.: Alimera: personal fees, Apellis: personal fees, Bayer: personal fees, non-financial support, Boehringer-Ingelheim: personal fees, Biogen: non-financial support, CenterVue: non-financial support, Chiesi: personal fees, Roche/Genentech: personal fees, non-financial support, Novartis: personal fees, non-financial support, ProQR: personal fees, Oxford Innovation: personal fees, Santhera: personal fees. F.H.: Acucela: personal fees, non-financial support, Allergan: non-financial support, Apellis: personal fees, non-financial support, Bayer: personal fees, non-financial support, Boehringer-Ingelheim: personal fees, Bioeq/Formycon: non-financial support, personal fees, CenterVue: non-financial support, Ellex: non-financial support, Roche/Genentech: personal fees, non-financial support, Geuder: personal fees, non-financial support, Graybug: personal fees, Gyroscope: personal fees, Heidelberg Engineering: personal fees, non-financial support, IvericBio: personal fees, non-financial support, Kanghong: personal fees, non-financial support, LinBioscience: personal fees, NightStarX: non-financial support, Novartis: personal fees, non-financial support, Optos: non-financial support, Oxurion: personal fees, Pixium Vision: personal fees, non-financial support, Oxurion: personal fees, Stealth BioTherapeutics: personal fees, Zeiss: non-financial support, personal fees, STZ GRADE Reading Center: Owner. S.S.V.: AlphaRET: personal fees, Apellis: personal fees, Bayer: non-financial support, Bioeq: personal fees, Carl Zeiss MediTec: non-financial support, Heidelberg Engineering: non-financial support, personal fees, Katairo: personal fees, Kubota Vision: personal fees, Novartis: personal fees, non-financial support, Oxurion: personal fees, Pixium: personal fees, Roche: personal fees, non-financial support, SparingVision: personal fees, STZ GRADE Reading Center: Owner. M.P.: Appelis: personal fees. S.T.: Heidelberg Engineering: personal fees, non-financial support; Optos: non-financial support, Zeiss: non-financial support, CenterVue: non-financial support; Novartis: personal fees; Bayer: personal fees; Allergan: personal fees.
